Walter Jeske, PhD | Loyola Medicine

COVID-19 (Coronavirus) Update

Loyola Medicine is resuming select health care services. Learn more about resumption of services.

Walter Jeske, PhD

Thoracic and Cardiovascular Surgery

Professor

Languages Spoken

English

Clinical Expertise

Biography

Interests

Medical Education

Medical School
Residency
Fellowship

Board Certification

Research

  • Advances in Heparins and Related Research. An Epilogue Fareed, J.; Bacher, P.; Jeske, W., Molecules (Basel, Switzerland)
  • Chemometric analysis of porcine bovine and ovine heparins., Ouyang, Y; Han, X; Yu, Y; Chen, J; Fu, L; Zhang, F; Linhardt, RJ; Fareed, J; Hoppensteadt, D; Jeske, W; Kouta, A; Zhang, Z; Xia, K, Journal of pharmaceutical and biomedical analysis
  • Comparative Pharmacokinetic Profile of 3 Batches of Ovine Low-Molecular-Weight Heparin and 1 Batch of Branded Enoxaparin. Jeske, W; Kouta, A; Duff, R; Rangnekar, V; Niverthi, M; Hoppensteadt, D; Fareed, J; Yao, Y, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
View All ResearchShow Less
  • Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device McClane, N.; Jeske, W.; Walenga, J. M.; Escalante, V.; Hoppensteadt, D.; Schwartz, J.; Bakhos, M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • The association between AB blood group and neonatal disease. McMahon, KE; Habeeb, O; Bautista, GM; Levin, S; DeChristopher, PJ; Glynn, LA; Jeske, W; Muraskas, JK, Journal of Neonatal-Perinatal Medicine
  • Comparison of Low-Molecular-Weight Heparins Prepared From Bovine Heparins With Enoxaparin Liu, X.; St Ange, K.; Fareed, J.; Hoppensteadt, D.; Jeske, W.; Kouta, A.; Chi, L.; Jin, C.; Jin, Y.; Yao, Y.; Linhardt, R. J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus Bhatt, D. L.; Grosser, T.; Dong, J. F.; Logan, D.; Jeske, W.; Angiolillo, D. J.; Frelinger, A. L., 3rd; Lei, L.; Liang, J.; Moore, J. E.; Cryer, B.; Marathi, U., Journal of the American College of Cardiology
  • Reply: Collapse of the Aspirin Empire: Is it Diabetic Gastroparesis or Cardioprotective Paresis? Bhatt, DL; Grosser, T; Dong, JF; Logan, D; Jeske, W; Angiolillo, DJ; Frelinger, AL; Liang, J; Cryer, B; Marathi, U, Journal of the American College of Cardiology
  • Reversal of new oral anticoagulants and personalized medicine. Iqbal, O; Jeske, W; Fareed, J, PERSONALIZED MEDICINE
  • Analysis of Heparins Derived From Bovine Tissues and Comparison to Porcine Intestinal Heparins St Ange, K.; Onishi, A.; Fu, L.; Sun, X.; Lin, L.; Mori, D.; Zhang, F.; Dordick, J. S.; Fareed, J.; Hoppensteadt, D.; Jeske, W.; Linhardt, R. J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Blood cell microparticles as biomarkers of hemostatic abnormalities in patients with implanted cardiac assist devices Jeske, W. P.; Walenga, J. M.; Menapace, B.; Schwartz, J.; Bakhos, M., Biomarkers in medicine
  • Synthetic organic compound vepoloxamer (P-188) potentiates tissue plasminogen activator, Dansdill, D.; Halandras, P. M.; Beverly, J.; Jeske, W.; Hoppensteadt, D.; Emanuele, M.; Fareed, J.; Cho, J. S., Journal of Vascular Surgery
  • Anticoagulant and Antithrombotic Actions of AVE5026 an Enriched Anti-Xa Hemisynthetic Ultra-Low-Molecular-Weight Heparin, Hoppensteadt, D. A.; Gray, A.; Jeske, W. P.; Walenga, J. M.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Compositional differences in commercially available prothrombin complex concentrates. Sadeghi, N; Kahn, D; Sayed, D; Hoppenstadt, D; Jeske, W; Harenberg, J; Dechristopher, P; Fareed, J, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Response to Protocol Review scenario: Need scientific justification. Valero, A; Jeske, W; Paulus, C, Lab animal
  • Sustained release of tissue factor following thrombosis of lower limb trauma Walenga, J. M.; Kaiser, P. C.; Prechel, M. M.; Hoppensteadt, D.; Jeske, W. P.; Misselwitz, F.; Bacher, P.; Lassen, M. R.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • The relationship between reticulated platelets intestinal alkaline phosphatase, and necrotizing enterocolitis, Kampanatkosol, R.; Thomson, T.; Habeeb, O.; Glynn, L.; Dechristopher, P. J.; Yong, S.; Jeske, W.; Maheshwari, A.; Muraskas, J., Journal of pediatric surgery
  • Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia Walenga, J. M.; Prechel, M.; Hoppensteadt, D.; Escalante, V.; Chaudhry, T.; Jeske, W. P.; Bakhos, M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Comparative studies on branded enoxaparin and a US generic version of enoxaparin Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Cunanan, J.; Khan, H.; Escalante, V.; Fareed, J.; Bakhos, M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction Govindan, S.; Kuster, D. W.; Lin, B.; Kahn, D. J.; Jeske, W. P.; Walenga, J. M.; Leya, F.; Hoppensteadt, D.; Fareed, J.; Sadayappan, S., American journal of cardiovascular disease
  • Left ventricular assist device-induced coagulation and platelet activation and effect of the current anticoagulant therapy regimen Ashbrook, M.; Walenga, J. M.; Schwartz, J.; Heroux, A.; Jeske, W. P.; Escalante, V.; Bakhos, M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Metabolic differences of current thienopyridine antiplatelet agents Fareed, J.; Jeske, W.; Thethi, I., Expert opinion on drug metabolism & toxicology
  • Tissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran rivaroxaban, and apixaban: potential clinical implication, Sadeghi, N.; Kahn, D.; Jeske, W.; Hoppensteadt, D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • A comparison of the pharmacodynamic behavior of branded and biosimilar enoxaparin in primates. Jeske, W.; Litinas, E.; Khan, H.; Hoppensteadt, D.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Interactions of oversulfated chondroitin sulfate (OSCS) from different sources with unfractionated heparin. Gray, A.; Litinas, E.; Jeske, W.; Fareed, J.; Hoppensteadt, D., Clinical & Applied Thrombosis/Hemostasis
  • Thromboelastographic evaluation of blood coagulation in the presence of branded and generic enoxaparins Walenga, J. M.; Jeske, W. P.; Escalante, V.; Hoppensteadt, D.; Fareed, J.; Bakhos, M., International angiology : a journal of the International Union of Angiology
  • A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin. Jeske, W. P.; Hoppensteadt, D.; Gray, A.; Walenga, J. M.; Cunanan, J.; Myers, L.; Fareed, J.; Bayol, A.; Rigal, H.; Viskov, C., Thrombosis research
  • Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels. Jeske, W. P.; Walenga, J. M.; Samama, M. M.; Hoppensteadt, D.; Mayuga, M.; Fareed, J., Blood Coagulation & Fibrinolysis
  • Simple scoring system for early management of heparin-induced thrombocytopenia. Messmore, H. L.; Fabbrini, N.; Bird, M. L.; Choudhury, A. M.; Cerejo, M.; Prechel, M.; Jeske, W. P.; Siddiqui, A.; Thethi, I.; Wehrmacher, W. H.; Walenga, J. M., Clinical & Applied Thrombosis/Hemostasis
  • A consensus conference on complex biologics and low molecular weight heparin Kalodiki, E.; Fareed, J.; Tapson, W. F.; Hoppensteadt, D. A.; Carter, C. A.; Sussman, I.; Parker, S.; Harenberg, J.; Hull, R.; Rao, G.; Lovinger, D. F.; Reid, L. D.; Kakkar, A.; Talarico, L.; Ofosu, F. A.; Bussey, H. I.; Fanikos, J.; Groce, J. B.; Skinner, N.; Ahluwalia, M.; Iqbal, O.; Jackson, C. M.; Jeske, W. P.; Ramacciotti, E.; Van Thiel, D.; Wahi, R.; Walenga, J., International Angiology
  • Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist Mousa, S. A.; Jeske, W. P.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Comparative studies on the topical administration of mucopolysaccharide and heparin ointments in nonhuman primates. Hoppensteadt, D. A.; Neville, B.; Schultz, C.; Jeske, W.; Raake, W.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative Kuziej, J.; Litinas, E.; Hoppensteadt, D. A.; Liu, D.; Walenga, J. M.; Fareed, J.; Jeske, W., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Laboratory methods and management of patients with heparin-induced thrombocytopenia. Prechel, M.; Jeske, W. P.; Walenga, J. M., Methods in Molecular Biology
  • Physiological changes in membrane-expressed platelet factor 4: implications in heparin-induced thrombocytopenia. Prechel, M. M.; Jeske, W. P.; Walenga, J. M., Thrombosis research
  • Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide. Adiguzel, C.; Iqbal, O.; Hoppensteadt, D.; Jeske, W.; Cunanan, J.; Litinas, E.; He, Z.; Walenga, J. M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin. Viskov, C.; Bouley, E.; Hubert, P.; Martinez, C.; Herman, F.; Jeske, W.; Hoppensteadt, D.; Walenga, J. M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products. Adiguzel, C.; Jeske, W. P.; Hoppensteadt, D.; Walenga, J. M.; Bansal, V.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. Akar, J. G.; Jeske, W.; Wilber, D. J., Journal of the American College of Cardiology
  • Are all low molecular weight heparins equivalent in the management of venous thromboembolism? Fareed, J.; Jeske, W.; Fareed, D.; Clark, M.; Wahi, R.; Adiguzel, C.; Hoppensteadt, D., Clinical & Applied Thrombosis/Hemostasis
  • Biological Profile of the Hyper/Oversulfated Chondroitin Sulfate Contaminant Isolated from Recalled Heparin Fareed, J.; Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Prechel, M.; Iqbal, O.; Adiguzel, C.; Clark, M.; Litinas, E.; cunanan, J.; Linhardt, R.; Harenberg, J., Seminars in thrombosis and hemostatis
  • Differentiating low-molecular-weight heparins based on chemical biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins, Jeske, W. P.; Walenga, J. M.; Hoppensteadt, D. A.; Vandenberg, C.; Brubaker, A.; Adiguzel, C.; Bakhos, M.; Fareed, J., Seminars in Thrombosis & Hemostasis
  • Inflammatory and hemostatic activation in patients undergoing off-pump coronary artery bypass grafting. Untch, B. R.; Jeske, W. P.; Schwartz, J.; Botkin, S.; Prechel, M.; Walenga, J. M.; Bakhos, M., Clinical & Applied Thrombosis/Hemostasis
  • Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate. Clark, M.; Hoppensteadt, D.; Walenga, J. M.; Myers, L.; Cunanan, J.; Jeske, W.; Adiguzel, C.; Iqbal, O.; Fareed, J., International Angiology
  • Potency Adjusted Generic Versions of Argatroban can be Differentiated from Branded Argatroban in Thrombin Generation and Platelet Activation Assays Adiguzel, C.; Iqbal, O.; Cunanan, J.; Jeske, W.; Hoppensteadt, D.; Walenga, J. M.; Fareed, J., Seminars in Thrombosis and Hemostasis
  • Rivaroxaban--an oral direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia., Walenga, J. M.; Prechel, M.; Jeske, W. P.; Hoppensteadt, D.; Maddineni, J.; Iqbal, O.; Messmore, H. L.; Bakhos, M., British journal of haematology
  • The anti-inflammatory effects of argatroban can be differentiated from other direct thrombin inhibitors: experimental and clinical observations. Hoppensteadt, D. A.; Jeske, W.; Walenga, J. M.; Bick, R. L.; Fareed, J., Seminars in Thrombosis and Hemostasis
  • The future of anticoagulation Hoppensteadt, D. A.; Jeske, W.; Walenga, J. M.; Fareed, J., Seminars in Respiratory & Critical Care Medicine
  • Heparin oligosaccharides as potential therapeutic agents in senile dementia Ma, Q.; Cornelli, U.; Hanin, I.; Jeske, W. P.; Linhardt, R. J.; Walenga, J. M.; Fareed, J.; Lee, J. M., Current pharmaceutical design
  • Isolation and characterization of heparin from tuna skins. Jeske, W. P.; McDonald, M. K.; Hoppensteadt, D. A.; Bau, E. C.; Mendes, A.; Dietrich, C. P.; Walenga, J. M.; Coyne, E., Clinical & Applied Thrombosis/Hemostasis
  • Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Ma, Q.; Tobu, M.; Schultz, C.; Jeske, W.; Hoppensteadt, D. A.; Walenga, J. M.; Cornelli, U.; Lee, J.; Linhardt, R.; Hanin, I.; Fareed, J., Thrombosis research
  • Troponin I levels in patients with preeclampsia. Joyal, D.; Leya, F.; Koh, M.; Besinger, R.; Ramana, R.; Kahn, S.; Jeske, W.; Lewis, B.; Steen, L.; Mestril, R.; Arab, D., American Journal of Medicine
  • Modulatory effects of Escherichia coli capsular-derived sulfaminoheparosans and heparins on tissue factor-mediated activation of platelets: flow cytometric analysis. Maddineni, J.; Jeske, W. P.; Baltasar, F.; Cornelli, U.; Manoni, M.; Hoppensteadt, D. A.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications Maddineni, J.; Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D. A.; Fareed, J.; Wahi, R.; Bick, R. L., Clinical & Applied Thrombosis/Hemostasis
  • Update on the clinical applications of argatroban. Fareed, J.; Jeske, W. P.; Hoppensteadt, D. A.; Walenga, J. M., Future Cardiology
  • Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. Prechel, M. M.; McDonald, M. K.; Jeske, W. P.; Messmore, H. L.; Walenga, J. M., Journal of Thrombosis & Haemostasis
  • Antiplatelet agents: current drugs and future trends Messmore, H. L., Jr; Jeske, W. P.; Wehrmacher, W.; Coyne, E.; Mobarhan, S.; Cho, L.; Leya, F. S.; Moran, J. F., Hematology - Oncology Clinics of North America
  • Comparative tissue factor pathway inhibitor release potential of heparins. Tobu, M.; Ma, Q.; Iqbal, O.; Schultz, C.; Jeske, W.; Hoppensteadt, D. A.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Development of generic low molecular weight heparins: a perspective Fareed, J.; Leong, W.; Hoppensteadt, D. A.; Jeske, W. P.; Walenga, J. M.; Bick, R. L., Hematology - Oncology Clinics of North America
  • Short- and long-acting synthetic pentasaccharides as antithrombotic agents Walenga, J. M.; Jeske, W. P.; Fareed, J., Expert opinion on investigational drugs
  • Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopenia Walenga, J. M.; Prechel, M.; Jeske, W. P.; Bakhos, M., Current opinion in pulmonary medicine
  • A survey of venous thrombosis models Jeske, W. P.; Iqbal, O.; Fareed, J.; Kaiser, B., Methods in Molecular Medicine
  • Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia Jeske, W. P.; Walenga, J. M., Methods in Molecular Medicine
  • Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs Walenga, J. M.; Jeske, W. P.; Prechel, M. M.; Bacher, P.; Bakhos, M., Seminars in Thrombosis & Hemostasis
  • Factor Xa inhibitors Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Fareed, J., Methods in Molecular Medicine
  • Generic low-molecular-weight heparins: some practical considerations Fareed, J.; Leong, W. L.; Hoppensteadt, D. A.; Jeske, W. P.; Walenga, J. M.; Wahi, R.; Bick, R. L., Seminars in Thrombosis & Hemostasis
  • Laboratory methods for heparin-induced thrombocytopenia. Prechel, M.; Jeske, W. P.; Walenga, J. M., Methods in Molecular Medicine
  • Newer insights on the mechanism of heparin-induced thrombocytopenia. Walenga, J. M.; Jeske, W. P.; Prechel, M. M.; Bakhos, M., Seminars in Thrombosis & Hemostasis
  • Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates. Jeske, W.; Fareed, J., Seminars in Thrombosis & Hemostasis
  • Small-molecule direct antithrombins: argatroban Fareed, J.; Jeske, W. P., Bailliere's Best Practice in Clinical Haematology
  • Benefit-risk assessment of treatments for heparin-induced thrombocytopenia Messmore, H.; Jeske, W.; Wehrmacher, W.; Walenga, J. M., Drug Safety
  • Factor Xa inhibitors: today and beyond Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Fareed, J., Current Opinion in Investigational Drugs
  • Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use. Tobu, M.; Iqbal, O.; Ma, Q.; Schultz, C.; Jeske, W.; Hoppensteadt, D.; Lewis, B.; Fareed, D.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice Fareed, J.; Hoppensteadt, D.; Walenga, J. M.; Iqbal, O.; Ma, Q.; Jeske, W.; Sheikh, T., Clinical pharmacokinetics
  • Pharmacodynamics and pharmacokinetics of C3 a heparin-derived oligosaccharide mixture, in non-human primates., Ma, Q.; Schultz, C.; Neville, B.; Jeske, W.; Hoppensteadt, D.; Cornelli, U.; Lee, J.; Lorens, S.; Hanin, I.; Fareed, J., Thrombosis research
  • Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test Wallock, M.; Jeske, W. P.; Bakhos, M.; Walenga, J. M., Perfusion